Navigation Links
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Date:3/13/2008

demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
2. Angiotech announces results for the fourth quarter ended December 31, 2007
3. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
5. Angiotech and Symphony Medical Announce Licensing Agreement
6. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
7. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
8. Angiotech to participate in RBC 2007 Healthcare Conference
9. Angiotech to participate in Bank of America 2007 Credit Conference
10. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
11. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  ArroGen Group, an integrated advanced ... Molecular Identification™ (FMID) technology Aug. 2-8 at the ... Sacramento, Calif. FMID, ... law enforcement agents, district attorneys and government agencies ... By analyzing chemical residues on fingerprints ...
(Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... the 35 th Annual Canaccord|Genuity Growth Conference in ... Petit, Chairman and CEO, William C. Taylor , ...
(Date:8/3/2015)... ... August 03, 2015 , ... The ... processed to get such derivatives as ethylbenzene, a precursor to styrene, used to ... the automotive industry for the production of tyres and other components. Thus, growth ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
... ,,, ... 26, 2010, QIAGEN N.V. (NASDAQ: ... Prime Standard: QIA [, http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ... an agreement with Roche Molecular Systems,Inc., ...
... increase crop yields and productivity, create sustainable forests and new medicines, and ... in the world,s poorest countries, will be among the recurring themes of ... Congress, June 6-11, 2010 , at the America,s Center ... , , ...
Cached Biology Technology:CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 2QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 3QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 5QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 6Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 2Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 3
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... uncovered an important step in how herpes simplex virus, ... to gain entry into healthy cells and infect them. ... the effectiveness of monitoring these protein interactions using biomolecular ... the National Academy of Sciences, provide a better understanding ...
... Access publisher for Physics, Mathematics and Computer Science, ... DESY high-energy physics laboratories. Under these agreements ... all research published by their investigators in the ... PMC Physics A is edited by professor Ken ...
... connect silicon circuits with brains are under intensive ... commercial application in many areas, according to a ... Berger of the University of Southern California chaired ... of Research and Development in Brain-Computer Interfaces," published ...
Cached Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2
... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
... is a genetically engineered Klenow polymerase in which ... removed, leaving only the 5 to 3 polymerase ... Klenow Fragment the enzyme of choice for isotopic ... random primed method, and for DNA sequencing by ...
Request Info...
Biology Products: